Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0268596 (EMA)
 2,520 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

An operable case of pedunculated localized mesothelioma of the pleura, a 62-year-old male, came to our clinic with chief complaint of chest X-ray abnormal shadow. On suspicion of pleural tumor, resection was performed. The operative findings revealed that the tumor was arising from visceral pleura of S1 + 2 a segment of left upper lobe, and didn't invade into peripheral tissue. The microscopic findings revealed that the tumor was consist of spindle tumor cells and capillary-like lesions, and had high cellularity and many mitosis. The tumor was diagnosed as localized malignant mesothelioma. Immunohistochemical stainings were performed using six monoclonal antibodies, vimentin, CEA, EMA, keratin (AE1, AE3), Leu-M1. Only vimentin reacted with tumor cells.
 ...
PMID:[An operated case of malignant localized mesothelioma of the pleura]. 140 76

Cutaneous lymphadenoma (CL) is a recently described neoplasm of unknown histogenesis. Histologically, these tumors typically present as well-circumscribed nodules with scant or no epidermal connections. They are composed of multiple rounded lobules of basaloid cells with some degree of peripheral palisading. These epithelial lobules characteristically show a dense lymphoid infiltrate within them. In cases of CL previously described, there was no obvious adnexal differentiation except for isolated cells showing apparent sebaceous differentiation or hints of follicular differentiation. We report two typical cases of CL that were studied histologically and immunohistochemically. In some of the tumor lobules, there were foci of ductal differentiation, with luminal positivity for CEA and EMA. We postulate that some CL represent a form of immature sweat gland tumor with ductal differentiation.
 ...
PMID:Cutaneous lymphadenoma with ductal differentiation. 147 94

Histological analyses of 16 autopsies of pancreatic carcinoma [9 cases after intra-arterial infusion chemotherapy (IAC), and 7 cases of systemic chemotherapy (SC)] were performed. Histological effects of chemotherapy (Shimosato) were seen in 15 cases, but less than 5 Grade II a. cases of IAC and 4 cases of SC showed Grade IIa, 3 cases of IAC and 3 cases of SC showed Grade I. The ratio of Grade IIa was almost the same in IAC and SC. But histologically, anaplastic change, sarcomatous change and Bizarre cells, immunohistologically positive to anti-EMA and Vimentin antibody, were dominant in IAC. And clinically, serum tumor markers (CEA, CA19-9) were fewer in almost all the cases in IAC. These results may suggest that the anti-tumor effect of IAC was greater than the histological appearance.
 ...
PMID:[Histological evaluation of intra-arterial infusion and systemic chemotherapy of pancreatic carcinomas]. 154 62

Gliosarcomas are mixed tumors with malignant glial and mesenchymal elements. The number of GFAP-positive tumor cells decreases with the increase of sarcomatous components, until whole areas may be GFAP negative. These distinct differentiations may, however, lead to false interpretations in small tissue samples. In this connection, it is of interest that, according to other reports, glial tumors may be positive for different anti-keratin antibodies and this prompted us to undertake a systematic investigation of the immunoreactivity of gliosarcomas using a panel of well-characterized monoclonal antibodies against cytokeratins (KL1, AE 1/3, Lu-5, CK-19, CK MNF 116 and Ma-903). These cases were further studied with the anti-epithelial non-cytokeratin antibodies EMA, HEA 125, Ber-EP4, CEA as well as the melanoma-antibody HMB-45, Leu-M1, GFAP and vimentin. As screening study we examined 20 cerebral metastatic carcinomas, 21 malignant gliomas (including 6 gliosarcomas) and 3 metastatic melanomas with the monoclonal antibodies KL1 and HMB-45. All cerebral metastatic carcinomas and 4/6 gliosarcomas were positive for KL1, whereas all melanomas, 2 metastatic carcinomas and 3 gliosarcomas showed an immunostaining with HMB-45. All gliosarcomas were positive with at least one of the tested anti-cytokeratin antibodies. The gliosarcomas did not show an immunoreaction in any of the cases when CEA, HEA 125, Ber-EP4, EMA or Leu M1 were applied. In our opinion, the monoclonal antibodies HEA 125 and Ber-EP4 could obviously be helpful in differentiating gliosarcomas from metastatic carcinomas.
 ...
PMID:Epithelial and melanoma antigens in gliosarcoma. An immunohistochemical study. 159 90

Six cases of vulvar Paget's disease (VP) with associated adenocarcinoma and 10 cases of VP without adenocarcinoma were compared immunohistochemically with B72.3, a pan-carcinoma marker developed against human mammary tumor cells, anti-carcinoembryonic antigen (anti-CEA), anti-epithelial membrane antigen (anti-EMA), anti-gross cystic disease fluid protein (anti-GCDFP-15), antihuman estrogen receptors (anti-ER), and anti-S-100 protein (anti-S-100). B72.3 reacted with 15/16 (94%) of the cases, anti-CEA reacted with 15/16 (94%), anti-EMA reacted with 16/16 (100%), anti-GCDFP-15 reacted with 14/16 (81%), and none of the 16 cases reacted with anti-ER or anti-S-100. There was no statistically significant difference in the percentage of cases binding antibodies between VP without adenocarcinoma and VP with adenocarcinoma. However, B72.3 and anti-CEA stained VP without adenocarcinoma significantly more strongly than VP with adenocarcinoma (p less than 0.05 and p less than 0.025). VP without adenocarcinoma tended to bind anti-GCDFP-15 more strongly than VP with adenocarcinoma, but without statistical significance. Paget cells stained differently than the cells in their associated adenocarcinoma in two of six cases. In both of these cases, the Paget cells and adenocarcinoma were noncontiguous. In contrast, three of the remaining four cases contained adenocarcinoma contiguous with Paget cells. Immunocytochemistry with B72.3 seems to be as useful as anti-GCDFP-15 in identifying VP.
 ...
PMID:Immunohistochemical features of Paget's disease of the vulva with and without adenocarcinoma. 165 67

64 diffuse pleural mesotheliomas diagnosed between 1964 and January 1985 at the Institute of Pathology of the University of Freiburg were analyzed. Since 1980 an increase from one case to 10 cases per year has been observed. The tumor was 3 to 4 times more frequent in men than in women. The age distribution showed a peak between the age of 50 and 60. In 26 cases evidence of exposure to asbestos was detected. In one patient radiotherapy of Hodgkin's disease may have been of etiological significance. The median survival time was 13 months. The five-year survival rate was only 4%. Histologic reevaluation was only possible in cases diagnosed after 1975. Of 43 cases thus evaluated 26 were pure mesothelial, 15 biphasic and 2 of the spindle-cell subtype. A median survival time of 23 months for pure mesothelial mesothelioma in comparison to 13 months for the biphasic mesothelioma indicated a better prognosis for pure mesothelial mesothelioma. Although no other primary tumors were detected, in 10 cases the differential diagnosis of adenocarcinoma had to be considered, and in 3 cases tumors of non-epithelial origin had to be excluded. 35 of 43 mesothelioma were CEA-negative, 38 out of 43 cytokeratin-positive, and 33 out of 43 were EMA-positive. Factor-VIII-related antigen was not demonstrated. 12 of 43 mesotheliomas showed PAS-positive staining, 29 of 43 were stained with Alcian blue. 7 of these 29 showed a positive digestion with hyaluronidase. Although CEA may not be negative in every mesothelioma, this marker seems to be a valid tool for the differential diagnosis of adenocarcinoma. In order to safeguard against a mistaken diagnosis of pleural mesothelioma, the exclusion of other tumors is always indispensable.
 ...
PMID:Malignant pleural mesothelioma: some aspects of epidemiology, differential diagnosis and prognosis. Histological and immunohistochemical evaluation and follow-up of mesotheliomas diagnosed from 1964 to January 1985. 169 Apr 13

Thirty-six cases of synovial sarcoma (13 biphasic and 23 monophasic) were subjected to a clinicopathologic study that included electron microscopy and immunohistochemistry. The group consisted of 21 males and 15 females ranging in age from 2 to 63 years. The majority of tumors (27 cases) were found in the hip and lower extremity. Immunohistochemical study revealed that keratin, which was detected in 92% of the biphasic and 57% of the monophasic tumors, was a more sensitive marker of epithelial differentiation than EMA or CEA. The overall 5-year survival of the patients was 64%. Male sex, older age, presence of tumor necrosis, monophasic pattern, and absence of keratin positivity had an unfavourable effect on survival but lacked statistical significance. Survival was significantly lower in patients with tumors exhibiting more than 15 mitoses per 10 HPF (P less than .02) and in those with tumors showing necrosis and a mitotic rate greater than 5 mitoses per 10 HPF (P less than .005).
 ...
PMID:Synovial sarcoma: a clinicopathological study of 36 cases. 169 34

One of the great challenges in the cytodiagnosis of effusions is the distinction between reactive mesothelium/histiocytes and cancer cells. This is notably true in patients having undergone radiation and/or chemotherapy. To establish whether monoclonal antibodies (MoAbs) could be used as reliable diagnostic adjuvants, the authors retrospectively and blindly studied 60 cases diagnosed by standard cytologic criteria (malignant, benign, and equivocal), with a panel of seven readily available MoAbs (cytokeratins, vimentin, EMA, B72.3, alpha-CEA, HMFG-2, and Leu-M1) and the lectin Ulex europaeus I. All 18 (100%) malignant cases showed reactivity with EMA and HMFG, whereas 17 (95%) and 11 (61%) reacted with B72.3 and alpha-CEA, respectively. Combinations of (1) EMA + B72.3, (2) EMA + alpha-CEA, and (3) EMA + alpha-CEA + B72.3 displayed positivity in 17 (95%), 11 (61%), and 10 (56%) malignant cases, respectively. Of the 18 benign cases, 7 reacted with HMFG and 2 each with EMA and B72.3. Only one case (5.5%) reacted with both EMA and B72.3. Based on these results, the 24 equivocal cases were regrouped into 14 malignant and 10 benign cases. Follow-up effusions obtained within the ensuing three months in all these patients allowed the authors to unequivocally confirm the diagnosis in all but five. The combination of EMA and B72.3 MoAbs detected malignant cells in 95% of the cases, with a 3.5% incidence of false positive cases in this study. A panel of EMA, B72.3, and alpha-CEA MoAbs should prove the most useful and simple approach to the correct diagnosis in most questionable effusions. Some of the potential pitfalls are discussed.
 ...
PMID:Immunocytochemical profile of benign and carcinomatous effusions. A practical approach to difficult diagnosis. 170 Aug 77

By using a series of antibodies, we studied the immunohistological hallmarks of eccrine and apocrine sweat glands. Antibodies raised against cytokeratins 6 and 18 decorated the eccrine glands except the acrosyringium. The anti-CEA Ab revealed a uniform and exclusive staining of the eccrine glands. The anti-cytokeratins 8, 18 and 19 Ab labelled the apocrine glands and the secretory part of the eccrine glands. The acrosyringia were revealed by anti-EMA Ab. The immunostaining with anti S-100 protein was positive for the secretory part of the eccrine glands.
 ...
PMID:[Immunohistochemistry and the sweat glands]. 170 71

The cytologic diagnosis of malignancy in serous effusions can be challenging. An immunocytochemical (ICC) panel using commercially available antibodies (to carcinoembryonic antigen [CEA], epithelial membrane antigen [EMA], B72.3, Leu-M1, cytokeratin [CK], leukocyte common antigen [LCA], S-100 protein, and vimentin) was applied to cell blocks fixed in methyl Carnoy's solution that were from 55 consecutive pleural, peritoneal, and pericardial fluid specimens. The results were correlated with data from clinical records and routine cytologic studies. Final cytologic diagnoses included 26 of adenocarcinoma and 1 of mesothelioma. The remaining 28 cases were considered to be benign (reactive) proliferations. EMA, CEA, B72.3, and Leu-M1 were present in 96%, 77%, 58%, and 42% of adenocarcinomas, respectively. These determinants were absent in the mesothelioma and the reactive effusions, although anti-CEA yielded strong background staining of inflammatory cells. The CK markers identified malignant cells in 93% of cases, but consistently stained mesothelial cells as well. Antivimentin strongly labeled mesothelial cells in all cases, with weak to absent staining of malignant cells. In 3 of 26 carcinoma cases (12%), the ICC panel identified malignant cells that were not recognized initially on routine cytologic examination. In 1 of 26 cases (4%), the panel was falsely negative. Use of this approach can improve the diagnostic accuracy of cytologic examination of serous fluids. The ICC panel is especially helpful when atypical mesothelial proliferation is present, or in cases that are clinically suspect for malignancy, but cytologically negative because there are only a few malignant cells, or those that are cytologically bland.
 ...
PMID:Immunocytochemical panel for the identification of malignant cells in serous effusions. 171 Apr 19


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>